Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lewis

Showing results (1111-1120 of 1,275) with videos related to

Pageof 128
Sort By:
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Heart (British Cardiac Society)|April 22, 2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) TrialKent R Nilsson, Sana M Al-Khatib, Yi Zhou, et al.
Stroke|March 29, 2014
Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke AssociationRobert G Holloway, Robert M Arnold, Claire J Creutzfeldt, et al.
Journal of the American College of Cardiology|April 17, 2026
Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart FailureYasuhiro Hamatani, Brian L Claggett, Akshay S Desai, et al.
Journal of Cardiac Failure|July 4, 2012
The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapyMahoto Kato, Lynne W Stevenson, Maryse Palardy, et al.
JAMA|March 13, 2013
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trialMihai Gheorghiade, Michael Böhm, Stephen J Greene, et al.
JACC. Heart Failure|January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney DiseaseIris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
European Journal of Heart Failure|October 2, 2015
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney diseaseNatalie A Bello, Eldrin F Lewis, Akshay S Desai, et al.
Endocrinology|November 15, 2012
Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammationChristine Tang, Anthony E Naassan, Astrid Chamson-Reig, et al.
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
Pageof 128

Showing results (1111-1120 of 1,275) with videos related to

Sort By:
Pageof 128
Circulation. Heart Failure|June 22, 2019
Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection FractionSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Heart (British Cardiac Society)|April 22, 2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) TrialKent R Nilsson, Sana M Al-Khatib, Yi Zhou, et al.
Stroke|March 29, 2014
Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke AssociationRobert G Holloway, Robert M Arnold, Claire J Creutzfeldt, et al.
Journal of the American College of Cardiology|April 17, 2026
Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart FailureYasuhiro Hamatani, Brian L Claggett, Akshay S Desai, et al.
Journal of Cardiac Failure|July 4, 2012
The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapyMahoto Kato, Lynne W Stevenson, Maryse Palardy, et al.
JAMA|March 13, 2013
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trialMihai Gheorghiade, Michael Böhm, Stephen J Greene, et al.
JACC. Heart Failure|January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney DiseaseIris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
European Journal of Heart Failure|October 2, 2015
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney diseaseNatalie A Bello, Eldrin F Lewis, Akshay S Desai, et al.
Endocrinology|November 15, 2012
Susceptibility to fatty acid-induced β-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between β-cell lipotoxicity and islet inflammationChristine Tang, Anthony E Naassan, Astrid Chamson-Reig, et al.
JAMA Cardiology|April 5, 2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF TrialAlvin Chandra, Eldrin F Lewis, Brian L Claggett, et al.
Pageof 128